14C AS A MARKER FOR BETA CELL TURNOVER IN ADULT HUMANS
14C AS A MARKER FOR BETA CELL TURNOVER IN ADULT HUMANS
批准号:
8362759
负责人:
John Tisdale
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2012-05-31
关键词:
AdultAgeAutoimmune ProcessBeta CellBlindnessBlood GlucoseBrainCellsChronic DiseaseDNADataDiseaseFundingGlucoseGrantHumanHuman Resources DevelopmentImmuneInsulinInsulin-Dependent Diabetes MellitusIslets of LangerhansKidney FailureLifeMeasurementMeasuresMediatingMyocardial IschemiaNational Center for Research ResourcesNatural regenerationNeuropathyNuclearOrganPancreasPatientsPrincipal InvestigatorProcessRecoveryResearchResearch DesignResearch InfrastructureResearch PersonnelResourcesSecondary toSourceStem cellsStrokeTechniquesTestingTherapeuticTissuesUnited States National Institutes of Healthaccelerator mass spectrometrycostembryonic stem cellglucose monitor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Type I diabetes mellitus (T1DM) results from an immune mediated destruction of the insulin producing beta cells (beta-cells) located in the pancreas in cell clusters called the islets of Langerhans. Since beta-cells are the only cells in the body that physiologically regulate and secrete insulin, their destruction causes a chronic disease state which necessitates frequent blood glucose monitoring and exogenous insulin therapy. It is very difficult but important for patients to maintain near normal blood glucose levels since high glucose levels are associated with severe end organ complications. These complications include renal failure, blindness, neuropathy, and large vessel atherosclerotic diseases like ischemic heart disease and stroke. Strategies that could promote beta-cell recovery or regeneration would represent an important therapeutic advance. Other investigators are attempting to develop an alternative source of insulin producing cells. However, while the question is critically important, whether the adult human pancreas can regenerate beta-cells remains unknown. For instance, if significant beta-cell regeneration is possible during post-natal or adult life, then strategies aiming to disrupt the autoimmune process underlying T1DM might reverse the disease. Additionally, data supporting beta-cell regeneration would support the notion that adult pancreatic stem cells exist and would support the search for such stem cells. Our hypothesis is that the adult pancreas maintains the capacity to continuously generate new beta-cells. Since changing atmospheric 14C levels (secondary to nuclear testing) over the past half century have been accurately tracked, the 14C incorporated into a tissue's DNA can be used to quantitate the age of that DNA (i.e. when that DNA was made) and thus the turnover rate of cells within that tissue. For example, this AMS 14C measurement within DNA has shown a surprising cell turnover rate in the human brain. We seek to test our hypothesis that beta-cells too are "turning over" by applying the AMS technique to measure 14C within cadaveric donor beta-cell DNA. AMS measurement of 14C in beta-cells of humans of different ages should enable us to answer whether beta-cells regenerate in adult humans. Data suggesting that beta-cells regenerate in adult human pancreata would promote research designed to further promote that process, and would spur efforts to identify the progenitor cell for the new beta-cells. Alternatively, if we find no evidence suggesting new beta-cells are created during adulthood, efforts would more appropriately be directed towards finding new sources for insulin producing cells (e.g. embryonic stem cells, cellular therapy, etc.).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A preclinical large animal model for globin gene transfer
-
批准号:10467904
-
项目类别:
-
资助金额:$116.21万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Isolation, characterization, and transplantation of candidate stem cells
-
批准号:8557973
-
项目类别:
-
资助金额:$58.6万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:8939814
-
项目类别:
-
资助金额:$51.78万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Isolation, characterization, and transplantation of candidate stem cells
-
批准号:9157366
-
项目类别:
-
资助金额:$56.41万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Nonmyeloablative allogeneic PBSC in globin disorders
-
批准号:7337573
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Nonmyeloablative allogeneic PBSC in globin disorders
-
批准号:7593475
-
项目类别:
-
资助金额:$56.02万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Isolation, characterization, and transplantation of candidate stem cells
-
批准号:7593477
-
项目类别:
-
资助金额:$32.01万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:8149537
-
项目类别:
-
资助金额:$91.16万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfe
-
批准号:7337576
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:7969163
-
项目类别:
-
资助金额:$41.15万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Isolation, characterization, and transplantation of candidate stem cells
-
批准号:8344826
-
项目类别:
-
资助金额:$61.31万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Nonmyeloablative allogeneic PBSC in globin disorders
-
批准号:8557971
-
项目类别:
-
资助金额:$132.25万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:10012680
-
项目类别:
-
资助金额:$83.87万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Nonmyeloablative allogeneic PBSC in globin disorders
-
批准号:10253825
-
项目类别:
-
资助金额:$144.37万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Development of improved lentiviral vectors for human gene therapy applications
-
批准号:7735061
-
项目类别:
-
资助金额:$16.48万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Nonmyeloablative allogeneic PBSC in globin disorders
-
批准号:10467903
-
项目类别:
-
资助金额:$154.94万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Development of improved lentiviral vectors for human gene therapy applications
-
批准号:7969167
-
项目类别:
-
资助金额:$20.58万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:8557972
-
项目类别:
-
资助金额:$102.13万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
Isolation, characterization, and transplantation of stem
-
批准号:7151527
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
A preclinical large animal model for globin gene transfer
-
批准号:7593476
-
项目类别:
-
资助金额:$48.02万
-
财政年份:--
-
负责人:John Tisdale
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: